Eisai Announces Japan MAH License from Nobelpharma for Antineoplastic Agent Gliadel 7.7mg Implant

Eisai Co., Ltd. ESALY announced today that it will receive the Marketing Authorization Holder (MAH) license for the antineoplastic agent Gliadel 7.7 mg Implant (carmustine, "Gliadel") in Japan from Nobelpharma Co., Ltd. (Headquarters: Tokyo, President & CEO: Jin Shiomura, "Nobelpharma"), effective December 2.In Japan, marketing authorization for Gliadel was first received in September 2012 by Nobelpharma after it conducted clinical trials of the agent. Eisai is responsible for domestic sales and distribution of Gliadel under an existing agreement with Nobelpharma and is also co-promoting the agent based on this collaboration, but has decided to act on a licensing option provided in the same agreement that allows Eisai to receive the current Japan MAH license for Gliadel from Nobelpharma. Following the transfer, both companies will continue to promote Gliadel domestically, but with Eisai also responsible for the marketing of the agent in Japan, including responding to the needs of healthcare professionals and ensuring and providing information See full press release